Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

40.28 +0.66 (+1.68%)
Streaming Delayed Price Updated: 10:01 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
What Does the Market Think About GSK?
 
Via Benzinga
How Is The Market Feeling About GSK?
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Earnings Scheduled For July 30, 2025
 
Via Benzinga
US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence
Via Stocktwits
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets. 
Via Benzinga
GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’
GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate. 
Via Stocktwits
Topics Artificial Intelligence World Trade
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion. 
Via Benzinga
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data
FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma. 
Via Benzinga
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
From GSK plc
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning
FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision. 
Via Benzinga
Dow Futures Edge Higher As Strong Earnings Boost Investor Confidence: AXP, NFLX, IBKR, GSK Among Stocks To Watch
While Dow Jones futures were up 0.07% at the time of writing, the S&P 500 futures were up 0.03%. 
Via Stocktwits
Topics ETFs Economy Government
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay Optimistic
Despite the setback, GSK defended the drug’s potential, citing strong results from DREAMM trials. 
Via Stocktwits
US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation
From GSK plc
Via Business Wire
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance
A decision by the FDA on the new submission is expected in the first half of 2026. 
Via Stocktwits
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge. 
Via Benzinga
Topics Lawsuit
GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years
Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré... 
Via Stocktwits
Topics Death Lawsuit
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
From GSK plc
Via Business Wire
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates. 
Via Stocktwits
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel
The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations. 
Via Stocktwits
Topics Government
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.